Sign In
Buy PODD
$143.30
+0.87 (+0.611%)
At Close: Jun 03, 2026
Here's Why You Should Retain Insulet (PODD) Stock for Now
11:30am, Friday, 24'th Sep 2021
Strong domestic and international performance by Omnipod is driving the top line for Insulet (PODD).
Insulet (PODD) Gains on Omnipod Sales Amid Cost Pressure
12:30pm, Tuesday, 07'th Sep 2021
Insulet (PODD) is gradually improving with respect to seamless supply chain and manufacturing operations.
Insulet's (PODD) Omnipod Gets FDA Nod for Use With Lyumjev
11:25am, Tuesday, 17'th Aug 2021
Insulet's (PODD) Omnipod is the only insulin pump to get approved for use with Lyumjev in the United States.
FDA Clears Use Of Eli Lilly's Insulin With Insulet's Infusion Pumps
03:01pm, Monday, 16'th Aug 2021
The FDA has approved the use of Eli Lilly And Co's (NYSE:LLY) Lyumjev (insulin lispro-aabc injection) 100 units/mL with Insulet Corporation's (NASDAQ:PODD) insulin management systems. Lyumjev, a
Insulet Introduces Omnipod DASH® System at Australasian Diabetes Congress
05:04pm, Wednesday, 11'th Aug 2021
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented
Insulet Corporation (PODD) CEO Shacey Petrovic on Q2 2021 Results - Earnings Call Transcript
02:42am, Friday, 06'th Aug 2021
Insulet Corporation (PODD) CEO Shacey Petrovic on Q2 2021 Results - Earnings Call Transcript
Insulet (PODD) Q2 Earnings Lag Estimates
07:01pm, Thursday, 05'th Aug 2021
Insulet (PODD) delivered earnings and revenue surprises of -16.67% and 2.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Insulet Reports Second Quarter 2021 Revenue Increase of 16% Year-Over-Year
04:01pm, Thursday, 05'th Aug 2021
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
3 Stocks to Buy That Should Get a Boost From Pandemic-Driven Consumer Weight Gain
10:41pm, Saturday, 31'st Jul 2021
Athletic-apparel maker Lululemon and two diabetes specialists are poised to get a long-term tailwind from the COVID-19 pandemic.
Insulet to Present at Upcoming Investor Conferences
06:00am, Monday, 26'th Jul 2021
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management
Insulet to Announce Second Quarter 2021 Financial Results on August 5, 2021
06:00am, Thursday, 01'st Jul 2021
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
Insulet (PODD) Reports Positive Study Outcomes on Omnipod 5
07:39am, Tuesday, 29'th Jun 2021
Insulet's (PODD) Omnipod 5 shows improved glycemic outcomes for users of all age groups and reduced diabetes distress in users and respective caregivers amid other benefits.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
Insulet to Present New Clinical Data for Preschool Children and Adults using the Omnipod® 5 System
06:00am, Thursday, 24'th Jun 2021
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced
Top 5 1st-Quarter Trades of Steve Mandel's Lone Pine
12:45pm, Thursday, 20'th May 2021
Lone Pine Capital, the hedge fund founded by Steve Mandel (Trades, Portfolio) in 1997, disclosed its first-quarter portfolio earlier this week.
